<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01707758</url>
  </required_header>
  <id_info>
    <org_study_id>13421</org_study_id>
    <nct_id>NCT01707758</nct_id>
  </id_info>
  <brief_title>Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence</brief_title>
  <official_title>Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to develop a rapid in vitro screening assay for detection of&#xD;
      pancreatic cancer biomarkers in blood of patients with pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of the project is to develop a rapid in vitro screening assay for detection of&#xD;
      cancer biomarkers in blood. The aim is testing and optimization of nanoparticle sensors,&#xD;
      based on cyanine dyes that are chemically linked to Fe/Fe3O4 nanoparticles via&#xD;
      protease-selective consensus (cleavage) sequences. The focus is on the quantitative&#xD;
      determination of active cancer-specific proteases in blood via simple fluorescence&#xD;
      measurements. The matrix metalloproteinases, urokinase-type plasminogen activator, and&#xD;
      cathepsins, are up-regulated in the vast majority of progressing cancers and can, therefore,&#xD;
      serve as markers for cell survival/tumor progression, angiogenesis, and tissue&#xD;
      remodeling/invasion&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Trial terminated - Nanoscale Company out of business&#xD;
  </why_stopped>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>pancreatic cancer</arm_group_label>
    <description>This study will collect blood from 36 patients with known or suspected pancreatic cancer and from 12 healthy cancer-free subjects.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Approximately 1 tablespoon of blood will be collected from each subject.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited from the University of Kansas Cancer Center prior to any&#xD;
        treatment for their pancreatic cancer. Final histology and staging will be recorded and&#xD;
        correlated with protease concnentration. Healthy subjects will be recruited from the&#xD;
        University of Kansas and Kansas State community.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria for Pancreatic Cancer Patients:&#xD;
&#xD;
          -  Patients will either have a histologic diagnosis of pancreatic carcinoma or a clinical&#xD;
             picture consistent with pancreatic cancer and will be undergoing surgery or a&#xD;
             diagnostic procedure to confirm the diagnosis.&#xD;
&#xD;
          -  Patients will have had no prior treatment or surgery&#xD;
&#xD;
        Inclusion Criteria for Healthy Subjects:&#xD;
&#xD;
          -  Subjects will have no prior history of any cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Exclusion Criteria for Pancreatic Cancer Patients&#xD;
&#xD;
          -  Any prior treatment for pancreatic cancer&#xD;
&#xD;
          -  Poorly controlled diabetes&#xD;
&#xD;
        Exclusion Criteria for Healthy Subjects&#xD;
&#xD;
          -  Poorly controlled diabetes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Williamson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center Cancer Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>October 12, 2012</study_first_submitted>
  <study_first_submitted_qc>October 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2012</study_first_posted>
  <last_update_submitted>May 15, 2013</last_update_submitted>
  <last_update_submitted_qc>May 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>nanoparticle</keyword>
  <keyword>proteases</keyword>
  <keyword>cell survival</keyword>
  <keyword>tumor progression</keyword>
  <keyword>angiogenesis</keyword>
  <keyword>tissue remodeling/invasion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

